Skip to main content
SpringerLink
Log in

Major vault protein/lung resistance-related protein (MVP/LRP) expression in nervous system tumors

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

Lung resistance-related protein (LRP) was identified as the major vault protein (MVP), the main component of multimeric vault particles. It functions as a transport-associated protein that can be associated with multidrug resistance. In previous studies, expression of MVP/LRP has been documented in tumors of various types. In general, good correlations have been reported for expression of MVP/LRP and decreased sensitivity to chemotherapy and poor prognosis. MVP/LRP expression has been documented in glioblastomas, but its expression in nervous system tumors in general has not been well characterized. Immunohistochemistry using anti-human MVP/LRP antibody (LRP-56) was performed on formalin-fixed, paraffin-embedded archival tissue from 69 primary central nervous system tumors. Expression of MVP/LRP was observed in 81.2% (56/69) of primary nervous system tumors, including astrocytomas (11/13), oligodendrogliomas (1/2), oligoastrocytomas (5/5), ependymoma (1/1), meningiomas (35/45), schwannomas (2/2), and neurofibroma (1/1). Various degrees and distributions of immunoreactivity to MVP/LRP were observed. Neither the presence nor the degree of immunoreactivity to MVP/LRP showed any correlation with either tumor grade or the presence of brain invasion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scheffer GL, Wijngaard PL, Flens MJ, et al (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578–582

    Article  PubMed  CAS  Google Scholar 

  2. Den Boer ML, Pieters R, Kazemier KM, et al (1999) Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia 13:2023–2030

    Article  Google Scholar 

  3. Kitazono M, Sumizawa T, Takebayashi Y, et al. (1999) Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647–1653

    Article  PubMed  CAS  Google Scholar 

  4. Xu D, Arestrom I, Virtala R, et al (1999) High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br J Haematol 106:627–633

    Article  PubMed  CAS  Google Scholar 

  5. Volm M, Mattern J, Koomagi R (1997) Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance. Anticancer Drugs 8:931–936

    Article  PubMed  CAS  Google Scholar 

  6. Hart SM, Ganeshaguru K, Scheper RJ, et al (1997) Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 25: 1227–1232

    PubMed  CAS  Google Scholar 

  7. Tews DS, Nissen A, Kulgen C, et al (2000) Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 50:227–237

    Article  PubMed  CAS  Google Scholar 

  8. Izquierdo MA, Scheffer GL, Flens MJ, et al (1996) Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148:877–887

    PubMed  CAS  Google Scholar 

  9. Michieli M, Damiani D, Ermacora A, et al (2000) P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol 108:703–709

    Article  PubMed  CAS  Google Scholar 

  10. Ogretmen B, Barredo JC, Safa AR (2000) Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 22:45–49

    Article  PubMed  CAS  Google Scholar 

  11. van Haselen CW, Flens MJ, Scheper RJ, et al (1999) Multidrug resistance related proteins in primary cutaneous lymphomas. Adv Exp Med Biol 457:119–131

    PubMed  Google Scholar 

  12. Rimsza LM, Campbell K, Dalton WS, et al (1999) The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leuk Lymphoma 34:315–324

    PubMed  CAS  Google Scholar 

  13. Alexander D, Yamamoto T, Kato S, et al (1999) Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 29:401–406

    PubMed  CAS  Google Scholar 

  14. van der Pol JP, Blom DJ, Flens MJ, et al (1997) Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines. Invest Ophthalmol Vis Sci 38:2523–2530

    PubMed  Google Scholar 

  15. Dingemans AM, van Ark-Otte J, van der Valk P, et al (1996) Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 7:625–630

    PubMed  CAS  Google Scholar 

  16. Uozaki H, Horiuchi H, Ishida T, et al (1997) Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336–2344

    Article  PubMed  CAS  Google Scholar 

  17. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, et al (2001) Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 165:130–135

    Article  PubMed  Google Scholar 

  18. Ohno N, Tani A, Uozumi K, et al (2001) Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood 98: 1160–1165

    Article  PubMed  CAS  Google Scholar 

  19. Efferth T, Bode ME, Schulten HG, et al (2001) Differential expression of the lung resistance-related protein/major vault protein in the histological compartments of nephroblastomas. Int J Oncol 19: 163–168

    PubMed  CAS  Google Scholar 

  20. Motoji T, Tsuji K, Wang Y, et al (2000) Significance of lung resistance-related protein in clinical outcome of acute leukemic patients with reference to p-glycoprotein. Exp Hematol 28:1499

    Article  Google Scholar 

  21. Tsuji K, Motoji T, Sugawara I, et al (2000) Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol 110:370–378

    Article  PubMed  CAS  Google Scholar 

  22. Borg AG, Burgess R, Green LM et al (1998) Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 103:1083–1091

    Article  PubMed  CAS  Google Scholar 

  23. Izquierdo MA, van der Zee AG, Vermorken JB, et al (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87:1230–1237

    PubMed  CAS  Google Scholar 

  24. Schroeijers AB, Scheffer GL, Flens MJ, et al (1998) Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Pathol 152:373–378

    PubMed  CAS  Google Scholar 

  25. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580

    PubMed  CAS  Google Scholar 

  26. Kyritsis AP (1996) Chemotherapy for meningiomas. J Neurooncol 29:269–272

    Article  PubMed  CAS  Google Scholar 

  27. Kaba SE, DeMonte F, Bruner JM, et al (1997) The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:271–275

    Article  PubMed  CAS  Google Scholar 

  28. Newton HB, Slivka MA, Stevens C (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165–170

    Article  PubMed  CAS  Google Scholar 

  29. Sugawara I, Akiyama S, Scheper RJ, et al (1997) Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112:23–31

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Neurosurgery Laboratory, Department of Neurosurgery, University of Virginia, PO Box 800212, 22908, Charlottesville, VA, USA

    Tsutomu Sasaki, Gerald R. Hankins & Gregory A. Helm

  2. Department of Bioengineering, University of Virginia, Charlottesville, VA, USA

    Gregory A. Helm

Authors
  1. Tsutomu Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald R. Hankins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory A. Helm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Sasaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sasaki, T., Hankins, G.R. & Helm, G.A. Major vault protein/lung resistance-related protein (MVP/LRP) expression in nervous system tumors. Brain Tumor Pathol 19, 59–62 (2002). https://doi.org/10.1007/BF02478928

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02478928

Key words

Search

Navigation